Zura Bio (NASDAQ:ZURA) Announces Quarterly Earnings Results

Zura Bio (NASDAQ:ZURA) released its quarterly earnings results on Tuesday. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.09, Zacks reports. The firm had revenue of $0.00 million during the quarter.

Zura Bio Price Performance

Shares of NASDAQ ZURA traded up $0.04 during midday trading on Thursday, reaching $1.37. 27,364 shares of the stock were exchanged, compared to its average volume of 368,766. The firm has a 50-day simple moving average of $1.48 and a two-hundred day simple moving average of $2.76. Zura Bio has a twelve month low of $1.07 and a twelve month high of $6.35.

Hedge Funds Weigh In On Zura Bio

An institutional investor recently raised its position in Zura Bio stock. Bank of America Corp DE grew its position in Zura Bio Limited (NASDAQ:ZURA) by 31.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 41,222 shares of the company’s stock after acquiring an additional 9,966 shares during the period. Bank of America Corp DE owned about 0.06% of Zura Bio worth $103,000 at the end of the most recent quarter. Institutional investors own 61.14% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on ZURA shares. HC Wainwright reissued a “neutral” rating and set a $5.00 price objective on shares of Zura Bio in a report on Tuesday, December 24th. Guggenheim reissued a “buy” rating and issued a $15.00 price objective on shares of Zura Bio in a report on Wednesday. Chardan Capital decreased their target price on Zura Bio from $12.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zura Bio in a research report on Wednesday, December 11th. Finally, Oppenheimer reissued an “outperform” rating and set a $19.00 price target (down from $20.00) on shares of Zura Bio in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Zura Bio currently has an average rating of “Buy” and a consensus target price of $15.00.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.